make minor updat estim zoeti follow compani first-
quarter releas wednesday morn overal number ahead estim
full-year guidanc re-affirmed believ top-lin growth come
year exceed market pace roughli thank steadi
innov portfolio breadth across geographi speci
believ stock intra-day move approxim overdon given
consist execut solid growth manag reiter expect
combin sale dermatolog portfolio surpass million year
illustr impact new product anim health howev manag
indic outsid key area companion-anim portfolio gener flattish
growth quarter believ may catalyst sell pressur
follow wednesday morn call despit remain impress steadi
stream innov suspect continu next two year manag
point diagnost global companion-anim busi area continu
high potenti maintain outperform rate zoeti given stabil
busi model prospect anoth year double-digit earn growth
light posit quarter re-affirmed guidanc increas full year
ep target cent top-lin commentari roughli
million better prior model first quarter margin commentari
gener line estim
geograph expect unit state grow versu last year
model previous expect intern segment increas
compar last year model previous
expect dermatolog parasiticid offer diminish growth driver
year livestock pick particularli swine busi global expect
livestock expand compar off-set slow companion-
anim last year previous model companion-anim
observ quarter
return equiti ttm
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
apoquel cytopoint combin million revenu first quarter year-over-year increas see
exhibit total million sequenti howev manag reiter sale expect indic
expect dermatolog sale reach million higher dermatolog sale apoquel
cytopoint million quarter balanc sale intern market manag reiter
simparica sale continu ramp expect excess million peak sale continu view
combin parasiticid dog cat simparica foundat signific opportun growth
given recent survey commentari
exhibit quarterli apoquel cytopoint sale present
 product busi slightli under-perform expect quarter growth compar
estim continu believ swine busi struggl last year rebound given
product improv new vaccin launch estim growth swine compar growth
also estim improv growth poultri compar view diagnost
livestock space potenti add top-lin growth medium long term although busi
invest mode least given manag commentari would appear among key livestock
categori dairi end-market pressur beef swine poultri appear improv
increas revenu million billion maintain ebit margin
assumpt lower tax rate estim basi point translat ep estim
increas
increas revenu estim million billion increas ebit
margin basi point ep estim increas
valuat stock thought
follow intra-day declin zoeti trade time updat ep estim compar post-
ipo averag time forward earn small-cap anim health peer virbac virp dechra dph
phibro vetoquinol veto averag time higher-growth veterinari peer
abaxi abax outperform time continu
impress manag steadi execut consist new product innov given magnitud
wednesday correct solid quarter reiter outperform rate summari revis model
shown exhibit
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling net incom excl non-recurring non-recurring tax non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
